Abstract
The RAS gene family is among the most studied and best characterized of the known cancer related genes. Of the three human RAS isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. KRAS mutations are one of the most dominant mutations at 7% to 80% for colorectal cancer, 25% to 87% for pancreatic cancer, and 25% to 48% for lung cancer. The impact of KRAS mutations on the prognosis and survival of patients with adenocarcinoma and other types of cancer stimulates a lot of scientific research on their developmental mechanisms. To further develop a protocol for the treatment of mutant KRAS cases in Kazkahstan we study KRAS mutations status in Kazakhstani colorectal cancer and pancreatic patients. In this article, we review the literature on the role of KRAS mutation testing for management of patients and demonstrate preliminary data on KRAS mutation status in Kasakhstani patients with colorectal and pancreatic cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
